Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies

A. Gottlieb,J. Lacour,N. Korman,S. Wilhelm,Y. Dutronc,A. Schacht,J. Erickson,L. Zhang,L. Mallbris,S. Gerdes
DOI: https://doi.org/10.1111/jdv.13990
2016-11-02
Journal of the European Academy of Dermatology and Venereology
Abstract:Biologics are effective for the treatment of psoriasis. However, treatment outcomes may differ among biologic‐naive patients and those switched from previous biological therapies.
What problem does this paper attempt to address?